Immunohistochemical Evaluation of GATA3 Expression in Tumors and Normal Tissues
2012/06/16 by Haiyan Liu, Jianhui Shi, Myra L. Wilkerson +1 · 28 citations
Medicine · #Metastasis and carcinoma case studies #Cancer Diagnosis and Treatment #Urinary and Genital Oncology Studies
paper · pdf · doi:10.1309/ajcp5uafmsa9zqbz
Abstract
GATA3 expression has been reported in urothelial and breast carcinomas; however, the published data on GATA3 expression in tumors from other organs are limited. Immunohistochemical evaluation of GATA3 expression in 1,110 carcinomas and 310 cases of normal tissue using tissue microarray sections, 48 breast and bladder biopsy specimens, and 53 breast fine-needle aspiration biopsy specimens was performed. Sixty-two of 72 urothelial carcinomas (86%) and 138 of 147 breast carcinomas (94%) tested positive for GATA3. All other cases, except for 2 of 96 endometrial carcinomas, tested negative for GATA3. On fine-needle aspiration biopsy samples, 88% of primary breast carcinomas and 82% of metastatic breast carcinomas tested positive for GATA3. Our study revealed that GATA3 is a sensitive and specific marker for the diagnosis of breast and urothelial carcinomas. When working on a tumor of unknown origin, GATA3 should be routinely included in the initial screening panel if either a breast or urothelial primary tumor is suspected.
Cited by
- The role of GATA3 in breast carcinomas: a review
- Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases
- TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer
- GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. [europepmc]
- GATA3 immunohistochemical expression in salivary gland neoplasms. [europepmc]
- GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. [europepmc]
- Loss of GATA3 in bladder cancer promotes cell migration and invasion. [europepmc]
- GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. [europepmc]
- The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. [europepmc]
- The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. [europepmc]
- Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers. [europepmc]
- Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. [europepmc]
- The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. [europepmc]
- Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites. [europepmc]
- Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. [europepmc]
- Breast metastasis from colorectal cancer treated by multimodal therapy: Case report and literature review. [europepmc]
- An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. [europepmc]
- A Neural Network Framework for Predicting the Tissue-of-Origin of 15 Common Cancer Types Based on RNA-Seq Data. [europepmc]
- TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. [europepmc]
- GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients. [europepmc]
- Cancer of Unknown Primary: Challenges and Progress in Clinical Management. [europepmc]
- Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer. [europepmc]
- Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance. [europepmc]
- Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer. [europepmc]
- Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma. [europepmc]
- Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. [europepmc]
- GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors. [europepmc]
- TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary? [europepmc]
Related